Health Economics And Outcomes Research (HEOR) Services Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Health Economics And Outcomes Research (HEOR) Services Market Trends and Insights

Growing Demand for Real-World Evidence for Reimbursement

Payers increasingly require real-world effectiveness data to justify premium pricing and coverage terms. The FDA’s 2024 guidance endorsing electronic health record and claims data for regulatory decision-making firmly positions RWD as a primary evidence stream.^{[1]U.S. Food and Drug Administration, “Use of Real-World Evidence to Support Regulatory Decision-Making,” fda.gov} The Centers for Medicare & Medicaid Services expanded outcomes-based contract structures to 40% more therapeutic areas than in 2023, raising the stakes for manufacturers that lack mature RWE programs. Europe’s HTA Regulation adds a second compliance layer by obliging multinational dossiers to include comparative effectiveness data across 27 member states. Collectively, these mandates shift budgets toward analytics platforms capable of transforming dispersed claims, registry, and device telemetry data into payer-ready economic narratives. Premium pricing commanded by specialized RWE boutiques highlights the urgency with which sponsors are closing evidence gaps ahead of post-launch price negotiations.

Expansion of HTA / Value-Based Care Frameworks

Global HTA bodies now evaluate therapies using broader societal value criteria, extending beyond traditional cost-per-QALY thresholds. The EU Joint Clinical Assessment, in effect since January 2025, establishes a harmonized evidence dossier for oncology and ATMPs while allowing member states to maintain price autonomy.^{[2]RTI Health Solutions, “EU Joint Clinical Assessment: Implications for Evidence Generation,” rti.org} Japan, South Korea, and China are strengthening HTA review depth, integrating budget impact and patient-reported outcomes. The French National Authority for Health’s 2025-2030 roadmap prioritizes AI screening tools to vet manufacturer submissions, signaling a digital transformation within the assessors themselves.^{[3]French National Authority for Health, “2025-2030 Strategic Plan,” has-sante.fr} In the United States, hospital systems enrolled in alternative payment models must demonstrate procedure-level cost-effectiveness, accelerating provider-led outcomes research purchases. Heightened methodological expectations push sponsors toward specialist consultants with credentialed pharmacoeconomists and multi-country data rights.

Surge in Novel Drug Launches & Clinical Trials

Clarivate’s 2025 “Drugs to Watch” lists 11 assets forecast to exceed USD 1 billion annual sales within two years of launch, spanning obesity, oncology, and gene therapy. Each modality poses unique modeling challenges; one-time gene therapies require lifetime horizon projections, while GLP-1 obesity drugs demand budget impact detail across public and private payer pools. Concurrently, decentralized and hybrid trials produce volumetric wearable and app data demanding advanced cleaning and linkage methods. ICON’s tokenization platform processes 10 billion annual patient transactions, feeding this data into economic models that assess therapy durability beyond short-run trial endpoints. Rising pipeline complexity, therefore, amplifies the demand for HEOR specialists who are conversant in both advanced analytics and disease-area nuances.

Generative-AI-Enabled Rapid Evidence Synthesis

Large language models are moving from proof-of-concept to production within HEOR workflows. ISPOR’s 2024 evaluation found that systematic reviews were 60% faster without a loss in quality. IQVIA’s AI Assistant ingests 530 million deidentified patient records, automatically scopes research questions, and drafts GRADE-compliant evidence summaries for human validation. Firms embed retrieval-augmented generation to detect safety signals across live claims feeds, creating near-real-time economic models that anticipate payer renegotiations. Regulators direct developers to maintain algorithm transparency and human oversight, codified in the FDA’s 2024 AI pharmacovigilance draft guidance. These compliance guardrails favor incumbents with robust validation infrastructure, widening the competitive gap against tech-lite boutiques.

Scarcity of Skilled HEOR Specialists

Industry surveys forecast a 35% global shortfall in qualified health economists by 2030 as demand outstrips academic pipeline output. Axtria alone plans to hire 1,000 data scientists in India to shore up modeling capacity. Wage premiums climb and project lead times lengthen, squeezing service-provider margins even as top-line demand accelerates. Specialized fields such as cell-therapy modeling suffer most because standard pharmacoeconomic curricula lag behind therapeutic innovation, forcing firms to retrain clinical statisticians on value-assessment frameworks.

Privacy Restrictions Limiting RWD Access

GDPR has curtailed cross-border patient-level data flows by 40% since 2024, compelling country-specific analyses and raising project duplication costs. HIPAA and a patchwork of US state privacy laws further constrain data linkages between payers, providers, and researchers. New national-security directives on genomic data transfers tighten controls in China and the United States. Smaller biotech companies, lacking dedicated privacy counsel, face prohibitive compliance burdens and may defer launch in markets where evidence demands outweigh internal capacity. Fragmented datasets reduce the statistical power of cost-effectiveness analyses, risking negative reimbursement decisions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service: Real-World Data Dominates, Market Access Accelerates

Real-World Data Analytics & Information Systems accounted for 37.35% of revenue in 2025, reflecting sponsors’ need for defensible economic evaluations grounded in routine-care evidence. Consultancies and CROs invest in scalable cloud architectures that query claims, registries, and wearables data in near real time, shortening evidence cycles and reducing manual abstraction labor. The segment benefits from regulators’ explicit endorsement of RWD, with FDA guidance accelerating purchase decisions among late-stage biotech developers. Competitive pressure spurs innovation: IQVIA rebadged its HTA Accelerator as Market Access Insights in 2024, bundling dossier automation with budget impact simulation. Looking ahead, automated platform adoption, regional data-access partnerships, and the integration of payer adjudication feeds will keep the segment expanding faster than the overall health economics and outcomes research services market, as sponsors double down on post-launch real-world performance monitoring.

Market Access & Reimbursement is the fastest-growing service line with a 16.82% CAGR through 2031. Rising HTA rigor and divergent sub-national payer rules require continuous benefit re-assessment, especially for one-time therapies whose value unfolds over decades. Vendors are embedding policy trackers and scenario engines that flag threshold breaches for list-price renegotiations, helping clients pre-empt formulary delisting risks. 

By Service Provider: Consultancies Lead, CROs Gain Ground

Consultancies retained 47.86% of % health economics and outcomes research services market share in 2025, thanks to entrenched C-suite relationships and strategy pedigree. Yet CROs expand at 15.05% CAGR on the back of integrated development offerings that bundle evidence planning with protocol design and site operations. The model promises seamless data flow from trial to launch, lowering handover risk and reducing vendor count. ICON’s Real World Intelligence suite, built on tokenized patient IDs, illustrates the convergence; it converts clinical database snapshots directly into payer-ready economic evidence.

Syneos Health similarly scales longitudinal data assets to inform portfolio strategy, price-volume negotiations, and real-time safety analytics. Boutique HEOR firms respond by specializing in high-uncertainty modalities, for example, cell and gene therapy annuity modeling, where agility trumps scale. M&A activity is set to intensify as platforms seek to fill gaps in therapeutic depth or secure regional data entitlements.

By End-User: Pharma Dominates, Providers Emerge

Biotech & Pharma Companies represent 55.42% of end-user demand in 2025, reflecting the sector's primary responsibility for generating health economic evidence to support regulatory submissions and reimbursement negotiations. However, healthcare providers exhibit the strongest growth trajectory, with a 14.46% CAGR through 2031, signaling the market's evolution toward provider-led outcomes research as value-based care adoption accelerates across global healthcare systems. This shift reflects providers' increasing need to demonstrate treatment effectiveness and cost-efficiency to payers, particularly as bundled payment models expand beyond traditional fee-for-service arrangements.

Government & HTA Agencies maintain steady demand for specialized assessment capabilities, with the EU's Joint Clinical Assessment implementation creating new evidence requirements across 27 member states. The Canadian Drug Agency's establishment in 2024, following CADTH's transition, exemplifies how government bodies are strengthening their HTA capabilities to manage pharmaceutical spending more effectively. Other End Users, including medical device manufacturers and digital health companies, represent emerging growth opportunities as these sectors face increasing pressure to demonstrate clinical and economic value. The end-user diversification suggests market maturation, where HEOR services are becoming essential across the broader healthcare ecosystem rather than remaining concentrated within pharmaceutical companies.

Geography Analysis

North America captured 45.95% revenue in 2025, underpinned by sophisticated reimbursement schemes that demand robust economic evidence. The FDA’s RWD framework validation propels analytic spending and cements the United States as the reference market for methodological standards. Canada’s transformation of CADTH into the Canadian Drug Agency strengthens national HTA capacity and is expected to widen economic scrutiny of specialty drugs. Shortfalls in data-science talent and wage inflation could temper regional growth; nonetheless, mid-term expansion remains resilient because pipeline intensity translates directly into HEOR workload.

Asia Pacific posts the fastest CAGR of 17.93% through 2031, driven by rising clinical-trial volume, drug-pricing reforms, and digital-health infrastructure upgrades. Japan’s 2025 drug-price adjustments tie reimbursement to real-world utilization, spurring pharmaceutical companies to adopt proactive budget-impact tracking. China’s NMPA alignment with ICH guidelines increases global dossier commonality, yet provincial tendering rules still require province-level evidence cuts. India’s RWD network pilots provide cost-effective data sources for multinationals seeking broader ethnic representation. Service providers are localizing staff and forging data-licensing ventures with hospital consortia to comply with data localization statutes.

Europe maintains a substantial share owing to the newly operational Joint Clinical Assessment, which standardizes the clinical-effectiveness components of submissions across 27 member states. While dossier unification reduces duplication, national payers retain price-setting autonomy, compelling sponsors to run country-specific budget-impact analyses. The French National Authority for Health’s AI evaluation program sets a precedent for algorithm-assisted appraisal, potentially accelerating the review of AI-ready dossiers. Middle East & Africa and South America display mixed trajectories. Saudi Arabia operationalized managed entry agreements, pulling in HEOR expertise to structure risk-sharing deals. Brazil’s judiciary overrules negative HTA recommendations in most patient litigation cases, inserting uncertainty that forces extensive scenario modeling. Vendors that master heterogeneous evidence rules position themselves for outsized wins as payer systems mature.

Regulatory Landscape

HEOR demand is being shaped by regulators and HTA bodies formalizing how real-world evidence (RWE) and health care economic information (HCEI) can be generated and shared for decision-making. In the United States, FDA actions spanning RWE and payer-facing communications have raised expectations around data provenance, transparency, and the appropriate use of electronic health records and medical claims data. The Inflation Reduction Act (IRA) pricing negotiation program also adds an evidence need set tied to CMS implementation timelines, including requirements connected to effectuation of Maximum Fair Prices for 2026 and beyond.

In Europe, Regulation (EU) 2021/2282 on Health Technology Assessment became applicable on January 12, 2025. It introduced Joint Clinical Assessment requirements for certain products and tightened the regulatory-HTA interface, which increases the value of early evidence planning across jurisdictions. Outside North America and Europe, payers and regulators are codifying HEOR submission expectations. For example, Saudi Food and Drug Authority guidance standardizes Economic Evaluation Studies and explicitly recognizes both randomized controlled trials and RWE as acceptable evidence sources, increasing the volume and formality of pharmacoeconomic documentation in reimbursement pathways.

Value Chain Analysis

The HEOR services value chain starts with evidence inputs and access rights, including clinical trial data, real-world data (claims, EHRs, registries, and device and digital sources), and patient-reported outcomes. Privacy, governance, and data-use agreements determine how these inputs can be processed. Service providers, including consultancies and CROs, convert these inputs into study protocols, systematic literature reviews, indirect treatment comparisons, economic models, budget impact analyses, and HTA and payer submission components. Quality systems and methodological standards act as the control layer that supports auditability and stakeholder confidence.

Downstream, deliverables flow to decision-makers such as biopharma market access teams, payers, formulary committees, and government and HTA agencies. These cycles are increasingly iterative as post-launch performance monitoring and value-based arrangements expand. Regulatory activity such as the FDA revised draft guidance (June 2026) on manufacturer communications with payors reinforces earlier upstream payer engagement around HCEI and investigational information. That shift brings HEOR work earlier into development planning and increases integration needs across clinical, regulatory, and commercialization functions. Operational bottlenecks focus on skilled talent availability and compliant access to multi-country RWD, which is driving more investment in automation, federated analytics, and repeatable evidence-generation workflows.

Market Opportunities and Future Outlook

A clear whitespace is emerging around standardized, implementation-ready frameworks that tie HEOR methods directly to value-based healthcare execution, rather than only reimbursement dossiers. In April 2026, ISPOR released the IMPACT checklist to integrate HEOR into the design, implementation, and evaluation of value-based healthcare initiatives. The checklist creates a practical reference point for providers, payers, and manufacturers building measurement and costing infrastructure, supporting service demand for outcomes metric selection, costing methods, and longitudinal evaluation design.

Another opportunity is expanding methods and platforms that make patient-centered value measures operational in routine evidence generation, including novel outcomes constructs and the associated data collection and linkage work. EU Joint Clinical Assessment requirements that took effect in January 2025, along with the expanding use of RWE in regulatory and payer settings, are pulling HEOR earlier in the product lifecycle. That is increasing demand for integrated evidence planning that connects clinical endpoint strategy, RWD acquisition, and payer-ready economic narratives. Providers that pair AI-enabled evidence synthesis with governance for privacy and model transparency are aligning with payer scrutiny on explainability and with cross-border data constraints, which favors federated, multi-jurisdiction analytics approaches.